Trials / Recruiting
RecruitingNCT05530096
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Standard of care | Participants will not receive any intervention in this study. Participants will receive standard of care therapy |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2027-09-01
- Completion
- 2028-09-01
- First posted
- 2022-09-07
- Last updated
- 2025-04-03
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05530096. Inclusion in this directory is not an endorsement.